Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators
- PMID: 26836578
- DOI: 10.1002/cmdc.201500566
Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators
Erratum in
-
Corrigendum: Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.ChemMedChem. 2016 Jul 19;11(14):1576. doi: 10.1002/cmdc.201600319. Epub 2016 Jun 30. ChemMedChem. 2016. PMID: 27435152 No abstract available.
Abstract
There is a significant amount of excitement in the scientific community around cancer immunotherapy, as this approach has renewed hope for many cancer patients owing to some recent successes in the clinic. Currently available immuno-oncology therapeutics under clinical development and on the market are mostly biologics (antibodies, proteins, engineered cells, and oncolytic viruses). However, modulation of the immune system with small molecules offers several advantages that may be complementary and potentially synergistic to the use of large biologicals. Therefore, the discovery and development of novel small-molecule modulators is a rapidly growing research area for medicinal chemists working in cancer immunotherapy. This review provides a brief introduction into recent trends related to selected targets and pathways for cancer immunotherapy and their small-molecule pharmacological modulators.
Keywords: antitumor agents; cancer immunotherapy; immune system modulators; small molecules.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
